# Directs the department of health to submit a report to the legislature on the feasibility of establishing a drug manufacturing program

**Bill ID:** A8345BB
**Session:** 2024
**Sponsor:** Jenifer Rajkumar
**Status:** In Assembly Committee
**PDF:** [A8345BB PDF](https://legislation.nysenate.gov/pdf/bills/2024/A8345BB)

## Summary

Directs the department of health to report to the legislature on the feasibility of entering into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs; makes related provisions.

---

## Full Text

S T A T E  O F  N E W  Y O R K
 ________________________________________________________________________
 
  8345--B
 
  2023-2024 Regular Sessions
 
  I N  A S S E M B L Y
 
  December 13, 2023
  ___________
 
 Introduced  by  M.  of A. RAJKUMAR, L. ROSENTHAL, SEAWRIGHT -- read once
  and referred to the Committee on Health -- recommitted to the  Commit-
  tee  on Health in accordance with Assembly Rule 3, sec. 2 -- committee
  discharged, bill amended, ordered reprinted as amended and recommitted
  to said committee -- again reported from said  committee  with  amend-
  ments, ordered reprinted as amended and recommitted to said committee
 
 AN  ACT  in  relation to requiring the department of health to report on
  the feasibility of establishing a generic drug  manufacturing  program
  aimed at reducing the cost of prescription drugs and to address short-
  ages in the market for generic prescription drugs
 
  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
  Section 1. On or before January first, two  thousand  twenty-six,  the
 department  of  health  shall  submit  a  report to the legislature that
 assesses the feasibility of establishing a  generic  drug  manufacturing
 program  aimed at reducing the cost of prescription drugs and to address
 shortages in the market for generic prescription drugs by directly manu-
 facturing generic prescription drugs and  selling  generic  prescription
 drugs  at  a  fair price. The report shall conduct an analysis of gover-
 nance structure options for manufacturing functions, including  charter-
 ing  a  private  organization, a public-private partnership, or a public
 board of directors.  Additionally, the report shall include, but not  be
 limited to an analysis of the:
  (a) feasibility of entering into a partnership with a drug manufactur-
 er to produce insulin and generic drugs for chronic and high-cost condi-
 tions;
  (b) feasibility of entering into a partnership with a drug manufactur-
 er to produce and make generic prescription drugs widely available;
  (c)  generic prescription drugs that would have the greatest impact on
 lowering drug costs to patients, including high-cost drugs, high  utili-

  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
  [ ] is old law to be omitted.
  LBD08090-04-4
 A. 8345--B  2
 
 zation  drugs,  or  drugs experiencing shortages in the market which the
 program may prioritize;
  (d)  amount  of  staff required to oversee and manage the partnerships
 for manufacturing or distribution of generic prescription drugs;
  (e) research and development costs and start up costs associated  with
 the generic drug manufacturing program; and
  (f)  volume  of  generic  prescription  drugs  and insulin that can be
 produced over the first five years of the program.
  ยง 2. This act shall take effect on the first of January next  succeed-
 ing one year after it shall have become a law.